Sign inThe company's October 6 webinar detailed an interim DSMB recommendation to complete its 33-subject hospital study as planned, with unblinding expected in early January 2027.
SEC filing
Firmonertinib failed to significantly improve progression-free survival over chemotherapy in the BICR analysis, though secondary measures showed some benefit.
SEC filing
Caribou said it will discontinue development of vispa-cel and CB-011 and cut its workforce as it reviews options including a possible sale or merger.
SEC filing
The Cayman Islands company handed over its China unit in exchange for data rights and funding of the DUBLIN-4 trial, retaining no cash payment and a minority SEED stake.
SEC filing
The company said the Study Start-Up Agreement with Thermo Fisher's clinical research business marks the start of formal preparations for the multiple sclerosis study.
SEC filing
The company said median progression-free survival reached 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone, and it is modifying the Phase 2 protocol.
SEC filing
BioLife stockholders received $11.25 in cash plus 0.1442 Repligen shares per share as the merger closed October 6, 2026.
SEC filing
Repligen finalized its purchase of BioLife Solutions on October 6, 2026, combining bioprocessing technology with cell and gene therapy processing tools.
SEC filing
Sanofi will pay Regeneron a $1.0 billion upfront fee and up to $7.0 billion in milestones under a sixth amendment to their antibody license deal, while the companies also settled a related lawsuit.
SEC filing
The Nasdaq-listed biotech registered common shares issuable to Armistice Capital under warrants from an August 2026 registered direct offering, with an exercise price of $1.65.
SEC filing
Shareholders at the September 30, 2026 meeting backed a reverse split option, a bigger equity incentive pool, and changes tied to a July 2026 private placement.
SEC filing
BioMarin said its completed Alesta Therapeutics acquisition will add about $283 million in IPR&D charges in the third quarter and about $320 million for all of 2026, with updated guidance to follow.
SEC filing
In an October 5, 2026 release, new board chair Thomas Jensen cited government funding, FDA designations and in-house manufacturing as reasons to advance the radiation drug candidate.
SEC filing
The financing backs Telomir's Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer after the FDA cleared the drug's IND.
SEC filing
The clinical-stage GSK-3 inhibitor developer filed an SEC registration statement on October 6, 2026, as it faces a Nasdaq minimum market value deficiency.
SEC filing
Hamill, who led Gilead's worldwide commercial operations, joins Entera's board effective December 1, 2026, replacing departing director Yonatan Malca.
SEC filing
At an October 6, 2026 special meeting, Quince stockholders approved conversion of Series C Preferred Stock, a charter amendment raising authorized shares, and new 2026 equity plans.
SEC filing
The phase II study combining DA-EPOCH chemotherapy with Jazz Pharmaceuticals' recombinant Erwinia asparaginase in newly diagnosed adult leukemia patients stays halted, per a registry update posted September 29, 2026.
SEC filing, ClinicalTrials.gov (2)
Harrow paid $30 million up front for the dry eye nasal spray, with up to $70 million more tied to future sales milestones.
SEC filing
The company stopped NCT03307980 for sponsor reasons, not safety or efficacy, and will move participants to a long-term follow-up study.
ClinicalTrials.gov
The company suspended the study after a pharmacokinetic finding, though it reports no new safety signal, as enrollment stood at 187 participants.
ClinicalTrials.gov
The filing, dated October 5, 2026, supplements Processa's July 2026 report on its Vidya Therapeutics acquisition with audited and interim financial statements plus pro forma data.
SEC filing
Adjusting for baseline disease severity via CSF NfL, Alterity says ATH434 50 mg slowed functional decline by about 52% versus placebo at Week 52.
SEC filing
The company reported full enrollment of 120 patients in the ALSTARS Trial, with topline data expected in early Q2 2027.
SEC filing
Immunome paid Bristol-Myers Squibb $20.0 million in cash and issued over 4.4 million shares to remove future payment obligations tied to varegacestat and AL101.
SEC filing
The clinical-stage biotech, which applied to list on Nasdaq under "LYCA," reported preliminary results for LCA-0061 and detailed its LYTAC pipeline in an October 5, 2026 S-1 filing.
SEC filing
Both hires, effective September 29, 2026, are tied to commercial preparations for Herlystic (OST-HER2; daznelimgene lisbac) ahead of expected regulatory decisions in the U.K., U.S., and Europe.
SEC filing
Texas Ibogaine Research Corporation will work with DEA-registered Benuvia Operations to pursue U.S. cGMP manufacture of pharmaceutical-grade ibogaine API.
SEC filing
The agreement adds to an existing $2 million facility and allows conversion of borrowed amounts into common stock at a price tied to recent trading levels or a $1.00 cap.
SEC filing
Axe Compute paid off $87.8 million in debt and agreed to $42.9 million in deferred payments to Duos while stretching its customer contract for the Columbus, Georgia data center from three to five years.
SEC filing
The medical technology company said September orders pushed open purchase orders to $5.4 million heading into fiscal 2027, alongside preliminary fourth-quarter and full-year revenue figures.
SEC filing
The board approved a one-time Series R Convertible Preferred Stock dividend meant to shield shareholders from dilution while Jaguar weighs strategic options.
SEC filing
The agency's recommendation follows its review of additional data from the Phase 3 sunRIZE study of ersodetug, which did not meet its primary or key secondary endpoints.
SEC filing
The clinical-stage immunology company priced an undisclosed share count as of October 5, 2026, with stock last trading at $93.19.
SEC filing (3)
The San Diego biotech reported a completed Rule 506(b) offering of rights to acquire securities, with 14 investors and a first sale date of August 16, 2026.
SEC filing
The company said the meeting outlined a path to pivotal development, with formal FDA meeting minutes expected within about 30 days and Phase 3 readiness work already underway.
SEC filing
AbbVie disclosed $216 million in third-quarter acquired IPR&D and milestones expense, cutting adjusted EPS guidance by $0.11 for both the quarter and the full year.
SEC filing
FDA requested additional data, including from an OPMD natural history study, ahead of finalizing the pivotal trial design in early 2027.
SEC filing
PMV Pharmaceuticals appointed Matt Eckler, Ph.D. as director on October 1, 2026, as the company prepares to file for accelerated approval of rezatapopt in the first quarter of 2027.
SEC filing
The NRx Pharmaceuticals subsidiary will test a single-day TMS protocol combined with NRX-101 for treatment-resistant depression under an FDA-approved trial.
SEC filing
Insmed reaffirmed full-year 2026 revenue guidance for BRINSUPRI and ARIKAYCE as it begins a search for a new finance chief.
SEC filing
Virtual Incision Corp, based in Lincoln, Nebraska, filed a Form D with the SEC disclosing a securities offering under Rule 506(b).
SEC filing
The trial, called QUELL-DME, will test the oral NLRP3 inhibitor alone and alongside anti-VEGF therapy in about 180 participants, with topline data expected in the second half of 2027.
SEC filing
The clearance satisfies a funding condition from Surrozen's 2025 private placement, with a second closing expected around October 20, 2026.
SEC filing
Tonix Pharmaceuticals disclosed that Dr. Reddy's Laboratories filed an ANDA with a Paragraph IV certification targeting four patents covering TONMYA sublingual tablets.
SEC filing
OPKO Health determined on October 1, 2026 that holders of its 3.75% Convertible Senior Notes due 2029 can convert through December 31, 2026, and said it will settle in common stock.
SEC filing